Ed Campanaro

901 total citations · 1 hit paper
8 papers, 693 citations indexed

About

Ed Campanaro is a scholar working on Infectious Diseases, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Ed Campanaro has authored 8 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Immunology. Recurrent topics in Ed Campanaro's work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ed Campanaro is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ed Campanaro collaborates with scholars based in United States, Austria and Russia. Ed Campanaro's co-authors include Robert D. Arbeit, Frank Tally, Dennis G. Maki, Barry I. Eisenstein, Ivor Byren, Sara Yankelev, Richard B. Evans, Eszter Nagy, Leopold Stiebellehner and Heimo Lagler and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Open Forum Infectious Diseases.

In The Last Decade

Ed Campanaro

8 papers receiving 668 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections

2004 568 citations Robert D. Arbeit, Dennis G. Maki et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ed Campanaro United States	4	527	309	168	151	145	8	693
Kerry Read New Zealand	7	417 0.8×	251 0.8×	178 1.1×	76 0.5×	139 1.0×	11	587
Maria Joyce United States	9	311 0.6×	183 0.6×	273 1.6×	89 0.6×	126 0.9×	16	574
Jacques Vouillamoz Switzerland	14	373 0.7×	131 0.4×	290 1.7×	109 0.7×	130 0.9×	24	577
H.‐J. Linde Germany	14	359 0.7×	227 0.7×	181 1.1×	47 0.3×	91 0.6×	29	657
David Altarac United States	6	405 0.8×	299 1.0×	154 0.9×	121 0.8×	103 0.7×	12	680
Kevin W. Ward United States	13	424 0.8×	315 1.0×	195 1.2×	258 1.7×	84 0.6×	26	885
Kim Credito United States	16	410 0.8×	165 0.5×	318 1.9×	308 2.0×	62 0.4×	27	776
Toyoko Oguri Japan	15	349 0.7×	135 0.4×	229 1.4×	95 0.6×	66 0.5×	85	626
T. Schülin Netherlands	14	249 0.5×	106 0.3×	304 1.8×	77 0.5×	54 0.4×	18	575
Sabrina Klein Germany	11	142 0.3×	155 0.5×	140 0.8×	75 0.5×	75 0.5×	28	498

Countries citing papers authored by Ed Campanaro

Since Specialization

Citations

This map shows the geographic impact of Ed Campanaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ed Campanaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ed Campanaro more than expected).

Fields of papers citing papers by Ed Campanaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ed Campanaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ed Campanaro. The network helps show where Ed Campanaro may publish in the future.

Co-authorship network of co-authors of Ed Campanaro

This figure shows the co-authorship network connecting the top 25 collaborators of Ed Campanaro. A scholar is included among the top collaborators of Ed Campanaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ed Campanaro. Ed Campanaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Wolfe, Cameron R., Jonathan Cohen, Anna Holmes, et al.. (2025). Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical Infectious Diseases. 81(3). 439–450. 1 indexed citations

Ison, Michael G., Debra F. Weinstein, Anna Holmes, et al.. (2023). Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE). Open Forum Infectious Diseases. 10(7). ofad314–ofad314. 7 indexed citations

Gupta, Deepali, et al.. (2023). 1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Schmidt, Peter, et al.. (2023). Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults. Infectious Diseases and Therapy. 12(5). 1365–1377. 2 indexed citations

Paguntalan, Helen, Zoltán Magyarics, Lynn Connolly, et al.. (2021). 633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19). Open Forum Infectious Diseases. 8(Supplement_1). S420–S420. 2 indexed citations

Magyarics, Zoltán, Johann Bartko, Harald Rouha, et al.. (2019). Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 63(8). 42 indexed citations

Byren, Ivor, et al.. (2012). Randomized Controlled Trial of the Safety and Efficacy of Daptomycin versus Standard-of-Care Therapy for Management of Patients with Osteomyelitis Associated with Prosthetic Devices Undergoing Two-Stage Revision Arthroplasty. Antimicrobial Agents and Chemotherapy. 56(11). 5626–5632. 70 indexed citations

Arbeit, Robert D., et al.. (2004). The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections. Clinical Infectious Diseases. 38(12). 1673–1681. 568 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact